Pantoprazole

CLINICAL USE

Gastric acid suppression

DOSE IN NORMAL RENAL FUNCTION

Oral: 20–80 mg in the morningIV: 40–160 mg daily; doses >80 mg in 2 divided doses

PHARMACOKINETICS

Molecular weight :383.4

%Protein binding :98

%Excreted unchanged in urine : 80 (as metabolites)

Volume of distribution (L/kg) :0.15

half-life – normal/ESRD (hrs) :1/2–3

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antifungals: absorption of itraconazole and ketoconazole reduced

ADMINISTRATION

Reconstition

10 mL sodium chloride 0.9%

Route

Oral, IV

Rate of Administration

2–15 minutes

Comments

Use within 12 hours of reconstitution Dilute to 100 mL with sodium chloride 0.9% or glucose 5%.(15.4 mg/mL) 1 mL contains 10 mg anhydrous morphine, 1.2 mg papaverine HCl, and 1.04 mg codeine HCl

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home